{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:35:53Z","timestamp":1793050553922,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40291-026-00876-z","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:52:03Z","timestamp":1788850323000},"page":"957-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2\u2212 Metastatic Breast Cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Chi-Yin","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincy","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious","family":"Anyanwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali A.","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois-Clement","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Marquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Sapunar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"876_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/jnci\/djac158","volume":"114","author":"L Gallicchio","year":"2022","unstructured":"Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A. Estimation of the number of individuals living with metastatic cancer in the United States. J Natl Cancer Inst. 2022;114:1476\u201383. https:\/\/doi.org\/10.1093\/jnci\/djac158.","journal-title":"J Natl Cancer Inst"},{"key":"876_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"876_CR3","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383:2557\u201370. https:\/\/doi.org\/10.1056\/NEJMra1307118.","journal-title":"N Engl J Med"},{"key":"876_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100567","volume":"44","author":"L Vaz-Goncalves","year":"2025","unstructured":"Vaz-Goncalves L, Marquart-Wilson L, Protani MM, Stephensen MT, Moore J, Morris MF, et al. Capturing breast cancer subtypes in cancer registries: insights into real-world incidence and survival. J Cancer Policy. 2025;44:100567. https:\/\/doi.org\/10.1016\/j.jcpo.2025.100567.","journal-title":"J Cancer Policy"},{"key":"876_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminoncol.2020.05.010","volume":"47","author":"EM Walsh","year":"2020","unstructured":"Walsh EM, Smith KL, Stearns V. Management of hormone receptor-positive, HER2-negative early breast cancer. Semin Oncol. 2020;47:187\u2013200. https:\/\/doi.org\/10.1053\/j.seminoncol.2020.05.010.","journal-title":"Semin Oncol"},{"key":"876_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/BCTT.S270799","volume":"12","author":"A Luque-Bolivar","year":"2020","unstructured":"Luque-Bolivar A, Perez-Mora E, Villegas VE, Rondon-Lagos M. Resistance and overcoming resistance in breast cancer. Breast Cancer (Dove Med Press). 2020;12:211\u201329. https:\/\/doi.org\/10.2147\/BCTT.S270799.","journal-title":"Breast Cancer (Dove Med Press)."},{"key":"876_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-1246-5","volume":"22","author":"A Zundelevich","year":"2020","unstructured":"Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22:16. https:\/\/doi.org\/10.1186\/s13058-020-1246-5.","journal-title":"Breast Cancer Res"},{"key":"876_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216198","volume":"24","author":"F Raheem","year":"2023","unstructured":"Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L. Metastatic ER+ breast cancer: mechanisms of resistance and future therapeutic approaches. Int J Mol Sci. 2023;24:16198. https:\/\/doi.org\/10.3390\/ijms242216198.","journal-title":"Int J Mol Sci"},{"key":"876_CR9","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1002\/cncr.32345","volume":"125","author":"D Dustin","year":"2019","unstructured":"Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125:3714\u201328. https:\/\/doi.org\/10.1002\/cncr.32345.","journal-title":"Cancer"},{"key":"876_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85. https:\/\/doi.org\/10.1186\/s13058-021-01462-3.","journal-title":"Breast Cancer Res"},{"key":"876_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10549-024-07507-3","volume":"209","author":"M Taya","year":"2025","unstructured":"Taya M, Merenbakh-Lamin K, Zubkov A, Honig Z, Kurolap A, Mayer O, et al. Beyond endocrine resistance: estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK\/c-Jun MDR1 pathway in breast cancer. Breast Cancer Res Treat. 2025;209:431\u201349. https:\/\/doi.org\/10.1007\/s10549-024-07507-3.","journal-title":"Breast Cancer Res Treat"},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.annonc.2025.11.002","volume":"37","author":"L Cabel","year":"2026","unstructured":"Cabel L, Berger F, Bachelot T, Pistilli B, Dalenc F, de la Motte RT, et al. Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. Ann Oncol. 2026;37:329\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.002.","journal-title":"Ann Oncol"},{"key":"876_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","volume":"207","author":"MA Bhave","year":"2024","unstructured":"Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+) HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat. 2024;207:599\u2013609. https:\/\/doi.org\/10.1007\/s10549-024-07376-w.","journal-title":"Breast Cancer Res Treat"},{"key":"876_CR14","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20:1757\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2332.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"876_CR15","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.67.3061.","journal-title":"J Clin Oncol"},{"key":"876_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00617-7","volume":"10","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary N, Chibly AM, Collier A, Martinalbo J, Perez-Moreno P, Moore HM, et al. CDK4\/6i-treated HR+\/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ Breast Cancer. 2024;10:15. https:\/\/doi.org\/10.1038\/s41523-024-00617-7.","journal-title":"NPJ Breast Cancer"},{"key":"876_CR17","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246\u201356. https:\/\/doi.org\/10.1200\/JCO.22.00338.","journal-title":"J Clin Oncol"},{"key":"876_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102642","volume":"121","author":"K Venetis","year":"2023","unstructured":"Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, et al. ESR1 mutations in HR+\/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing. Cancer Treat Rev. 2023;121:102642. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102642.","journal-title":"Cancer Treat Rev"},{"key":"876_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11579","volume":"7","author":"JM Spoerke","year":"2016","unstructured":"Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016;7:11579. https:\/\/doi.org\/10.1038\/ncomms11579.","journal-title":"Nat Commun"},{"key":"876_CR20","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","volume":"28","author":"SM Tolaney","year":"2022","unstructured":"Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, et al. Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant. Clin Cancer Res. 2022;28:1500\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3276.","journal-title":"Clin Cancer Res"},{"key":"876_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2410858.","journal-title":"N Engl J Med"},{"key":"876_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025;393:569\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2502929.","journal-title":"N Engl J Med"},{"key":"876_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N Engl J Med. 2025;393:556\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2505725.","journal-title":"N Engl J Med"},{"key":"876_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","volume":"2","author":"S Chandarlapaty","year":"2016","unstructured":"Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2:1310\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1279.","journal-title":"JAMA Oncol"},{"key":"876_CR25","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8:1390\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0264.","journal-title":"Cancer Discov"},{"key":"876_CR26","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.23.00638","volume":"41","author":"HJ Burstein","year":"2023","unstructured":"Burstein HJ, DeMichele A, Somerfield MR, Henry NL, Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41:3423\u20135. https:\/\/doi.org\/10.1200\/JCO.23.00638.","journal-title":"J Clin Oncol"},{"key":"876_CR27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.tranon.2017.07.004","volume":"10","author":"T Takeshita","year":"2017","unstructured":"Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, et al. Comparison of ESR1 mutations in tumor tissue and matched plasma samples from metastatic breast cancer patients. Transl Oncol. 2017;10:766\u201371. https:\/\/doi.org\/10.1016\/j.tranon.2017.07.004.","journal-title":"Transl Oncol"},{"key":"876_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.625636","volume":"11","author":"L Urso","year":"2021","unstructured":"Urso L, Vernaci G, Carlet J, Lo Mele M, Fassan M, Zulato E, et al. ESR1 gene mutation in hormone receptor-positive HER2-negative metastatic breast cancer patients: concordance between tumor tissue and circulating tumor DNA analysis. Front Oncol. 2021;11:625636. https:\/\/doi.org\/10.3389\/fonc.2021.625636.","journal-title":"Front Oncol"},{"key":"876_CR29","unstructured":"Faslodex\u00ae (fulvestrant) prescribing information. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021344s015lbl.pdf. Accessed 15 Jan 2026."},{"key":"876_CR30","unstructured":"Orserdu\u2122 (elacestrant) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217639s000lbl.pdf. Accessed 15 Jan 2026"},{"key":"876_CR31","unstructured":"Inluriyo (imlunestrant) prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218881s000lbl.pdf. Accessed 15 Jan 2026."},{"key":"876_CR32","unstructured":"Database characterization guide. Flatiron.com: Flatiron Health. 2025. https:\/\/flatiron.com\/database-characterization. Accessed 15 Jan 2026."},{"key":"876_CR33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"876_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188315","volume":"1872","author":"O Najim","year":"2019","unstructured":"Najim O, Seghers S, Sergoynne L, Van Gaver H, Papadimitriou K, Wouters K, et al. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: a systematic review and meta-analysis of randomized and non-randomized trials. Biochim Biophys Acta (BBA) Rev Cancer. 2019;1872:188315. https:\/\/doi.org\/10.1016\/j.bbcan.2019.188315.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"key":"876_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00026","volume":"7","author":"T Reinert","year":"2017","unstructured":"Reinert T, Saad ED, Barrios CH, Bines J. Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer. Front Oncol. 2017;7:26. https:\/\/doi.org\/10.3389\/fonc.2017.00026.","journal-title":"Front Oncol"},{"key":"876_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","volume":"126","author":"SK Herzog","year":"2022","unstructured":"Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126:174\u201386. https:\/\/doi.org\/10.1038\/s41416-021-01564-x.","journal-title":"Br J Cancer"},{"key":"876_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.587671","volume":"10","author":"H Liao","year":"2020","unstructured":"Liao H, Huang W, Pei W, Li H. Detection of ESR1 mutations based on liquid biopsy in estrogen receptor-positive metastatic breast cancer: clinical impacts and prospects. Front Oncol. 2020;10:587671. https:\/\/doi.org\/10.3389\/fonc.2020.587671.","journal-title":"Front Oncol"},{"key":"876_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104878","author":"P Neven","year":"2025","unstructured":"Neven P, Mattar A, Cussac AL, Curigliano G, Harbeck N, O\u2019Shaughnessy J, et al. 306P Imlunestrant with or without abemaciclib as first-and second-line therapy in advanced breast cancer (ABC): a subgroup analysis from the EMBER-3 trial. ESMO Open. 2025. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104878.","journal-title":"ESMO Open"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00876-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00876-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:01:00Z","timestamp":1793048460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00876-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00876-z","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work and the journal\u2019s Open Access Charges were supported by Eli Lilly and Company.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chi-Yin Liao, Jincy John, Precious Anyanwu, Tyler Marquart, Francisco Sapunar, Aarti Chawla, and Lindsay A. Williams are employees and stockholders of Eli Lilly and Company. Manali A. Bhave reported a consulting\/advisory\/speaker role for AstraZeneca, Daiichi-Sankyo, Eli Lilly and Company, Pfizer, OncLive, Curio, Targeted Oncology, and Merck. Francois-Clement Bidard reported consulting fees from AstraZeneca, Daiichi-Sankyo, Roche, Tempus, Hengrui, Pfizer, and Relay TX; honoraria for lectures from AstraZeneca, Daiichi-Sankyo, Pfizer, and Roche; research grants from Pfizer, AstraZeneca, Natera, Novartis, Prolynx, SAGA Dx, Roche, and Personalis; and support for attending meetings from AstraZeneca, Daiichi-Sankyo, and Eli Lilly and Company.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used de-identified data and was not considered human subjects research under the Common Rule; therefore, institutional review board approval was not required. Permission to access the database for this study was obtained from Flatiron Health.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used for the current study were provided by the Flatiron Health Research Database to Eli Lilly and Company. The data license agreement does not permit sharing of datasets with people external to the study team. Requests for data sharing by license or by permission for the specific purpose of replicating results in this article can be submitted to PublicationsDataAccess@flatiron.com.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article. C-YL, JJ, AC, and LAW led the study conceptualization and design, and FS contributed to the study design. JJ and LAW contributed to data acquisition. All authors were involved in data interpretation. C-YL, PA, AC, and LAW contributed to drafting the manuscript. All authors critically reviewed the manuscript for important intellectual content. The authors take full responsibility for the integrity of the work as a whole, have approved the final version for publication, and had full control over the content, including final decisions on all aspects of the publication.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}